Results 101 to 110 of about 12,566,431 (163)

Pharmacokinetic model-based assessment of factor IX prophylaxis treatment regimens in severe hemophilia B. [PDF]

Sci Rep
Vandewalle B, Castaman G, Álvarez-Román MT, Ettingshausen CE, Nemes L, Tomic R, Martins P, Rodrigues JF, Pinachyan K.   +8 more
europepmc   +1 more source

Factor IX(a) inhibitors: an updated patent review (2003-present). [PDF]

Expert Opin Ther Pat, 2022
Afosah DK, Ofori E, Mottamal M, Al-Horani RA.   +3 more
europepmc   +1 more source

Omani experience with the use of factor IX Fc fusion protein. [PDF]

BMJ Case Rep, 2021
Alzadjali SI, Wali Y.
europepmc   +1 more source

Evidence for factor IX‐independent roles for factor XIa in blood coagulation

Journal of Thrombosis and Haemostasis, 2013
A. Matafonov, A. Matafonov, Qiufang Cheng, Yipeng Geng, I. Verhamme, Obi Umunakwe, E. Tucker, Mao-fu Sun, Vladimir Serebrov, A. Gruber, David Gailani   +10 more
semanticscholar   +1 more source

Soluble expression of recombinant coagulation factor IX protein using Escherichia coli. [PDF]

Biochem Biophys Rep
Park BH, Yun H, Jeong HJ.
europepmc   +1 more source

[Corrigendum] miR‑647 and miR‑1914 promote cancer progression equivalently by downregulating nuclear factor IX in colorectal cancer. [PDF]

Mol Med Rep, 2022
Liu S, Qu D, Li W, He C, Li S, Wu G, Zhao Q, Shen L, Zhang J, Zheng J.   +9 more
europepmc   +1 more source

Matching-Adjusted Indirect Comparison of Recombinant Factor IX Albumin Fusion Protein Versus Recombinant Factor IX Fc Fusion Protein for Weekly Prophylactic Treatment of Hemophilia B. [PDF]

Adv Ther
Guillet B, Yan S, Hooper B, Drelich D, Steenkamp J, Tomic R, Mancuso ME.   +6 more
europepmc   +1 more source

Probing activation-driven changes in coagulation factor IX by mass spectrometry. [PDF]

J Thromb Haemost, 2021
Freato N, van Alphen FPJ, Boon-Spijker M, van den Biggelaar M, Meijer AB, Mertens K, Ebberink EHTM.   +6 more
europepmc   +1 more source

Field Study and Correlative Studies of Factor IX Variant FIX-R338L in Participants Treated with Fidanacogene Elaparvovec. [PDF]

Thromb Haemost
Pittman DD, Carrieri C, Soares H, McKay J, Tan CY, Liang JZ, Rakhe S, Marshall JC, Murphy JE, Gaitonde P, Rupon J.   +10 more
europepmc   +1 more source

PBPK modeling of recombinant factor IX Fc fusion protein (rFIXFc) and rFIX to characterize the binding to type 4 collagen in the extravascular space. [PDF]

CPT Pharmacometrics Syst Pharmacol
Cloesmeijer ME, Sjögren E, Koopman SF, Lenting PJ, Cnossen MH, Mathôt RAA, OPTI‐CLOT study group and SYMPHONY consortium.   +6 more
europepmc   +1 more source